跳至主要内容
临床试验/NCT04327063
NCT04327063已完成3 期

A Double-blind Randomized Trial of Interpectoral Nerve Block (Pecs 1 and 2) With Ropivacaine Versus Placebo Before Breast Cancer Surgery: Effects on Acute Postoperative Pain. (MIRs 04)

Institut Curie4 个研究点 分布在 1 个国家目标入组 182 人开始时间: 2020年8月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
182
试验地点
4
主要终点
To compare the effect of ropivacaine versus placebo pectoral nerve block (Pecs 1 and 2) on acute pain after tumorectomy plus sentinel lymph node dissection on one day surgery

研究概览

简要总结

Compare the effect of ropivacaine versus placebo pectoral nerve block (Pecs 1 and 2) on acute pain after tumorectomy plus sentinel lymph node dissection on one day surgery.

详细描述

Before surgery, the 3rd interpectoral space will be identified. After aspiration, half of the solution of Ropivacaine 5 mg/ml not exceeding 3 mg/kg of maximal dose and 30 ml of maximal volume or saline (not exceeding 30 ml of maximal volume) will be injected into the interpectoral space underneath the pectoralis major muscle for the Pecs 1 block. The other half of the solution will be injected above the serratus anterior muscle at the third rib.

Evaluation of the percentage of patients treated with step 2 or 3 analgesics during the three postoperative hours.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

Double

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women with non-metastatic invasive breast carcinoma or breast carcinoma in situ treated by breast-conserving surgery (tumorectomy) with sentinel node technique on one day surgery.
  • Age between 18 and 85 years.
  • ASA class 1, 2 or 3
  • Signed informed consent form.

排除标准

  • Ongoing neoplasm or history of neoplasm other than breast cancer with the exception of: basal cell carcinoma, cervical carcinoma in situ, other treated cancer that has not relapsed during the 5 years preceding inclusion in the trial.
  • Axillary dissection planned during surgery planning
  • All bilateral surgery the day of Pecs administration
  • Metastatic breast carcinoma at diagnosis (M1).
  • Allergy to local anesthetics and morphine.
  • Use of analgesics during the 12 hours preceding the surgical procedure.
  • History of ipsilateral surgery during the previous 6 months.
  • History of substance abuse.
  • Pregnant woman or breastfeeding.
  • Subjects deprived of their liberty or under guardianship (including temporary guardianship).
  • Subjects no covered by social security scheme
  • Experiencing any psychiatric condition or major cognitive impairment that may hamper completion of self-reported questionnaires.
  • There is no prohibition for people to take part simultaneously in another search and there is no exclusion cause at the end of the research period

研究组 & 干预措施

Placebo

Placebo Comparator

Saline (30 mL maximum)

干预措施: Saline (Drug)

Ropivacaïne

Experimental

Ropivacaïne 5 mg/mL (not to exceed 3 mg/kg and 30 ml of maximal volume)

干预措施: Ropivacaine (Drug)

结局指标

主要结局

To compare the effect of ropivacaine versus placebo pectoral nerve block (Pecs 1 and 2) on acute pain after tumorectomy plus sentinel lymph node dissection on one day surgery

时间窗: 3 hours

Percentage of patients treated with step 2 or 3 analgesics during the first three postoperative hours after tumorectomy plus sentinel lymph node dissection, between the group with Ropivacaïne and the group with placebo

次要结局

  • Evaluation of acute pain at rest and after shoulder movement until 48 postoperative hours(48 hours)
  • Evaluation of acute pain until 48 postoperative hours(48 hours)
  • Evaluation of patient's satisfaction on pain management(48 hours)
  • Evaluation of Remifentanil consumption during anesthesia(3 hours)
  • Evaluation of analgesic consumption during the first 48 postoperative hours(48 hours)
  • Evaluation of the incidence of nausea and vomiting during the first 48 postoperative hours(48 hours)
  • Evaluation of complications of Pecs during 48 postoperative hours(48 hours)
  • Evaluation of the incidence of serious adverse events during 30 days(30 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验